Beam Therapeutics Outlines Pipeline and Cash Runway at Citi Summit

Beam Therapeutics outlined development timelines for its base-editing pipeline and reported a cash runway extending into mid-2029 during an appearance at the Citigroup Biopharma Back to School Summit. Alongside the regulatory updates, Beam Therapeutics Inc (BEAM) shares traded at $24.37, falling 3.20% from a previous close of $25.18, as of September 10, 2026, according to Finnhub market data.

"This is the first time, as far as we know in history, that we have a drug that can not just intervene genetically, which has been the new wave of medicine, but literally rewrite a sequence of the genome back to normal," said John Evans, Chief Executive Officer, Beam Therapeutics, in a transcript of the event.

Pipeline and Regulatory Milestones

The company highlighted several clinical programs spanning genetic diseases, led by progress in sickle cell disease and alpha-1 antitrypsin deficiency. Management detailed expectations for regulatory filings and trial enrollment across its primary assets during the conference presentation.

• Risto-cel: Beam Therapeutics expects a Biologics License Application filing for sickle cell disease around the end of 2026, though executives noted a possible slip into early 2027.
• BEAM-302: The alpha-1 antitrypsin deficiency treatment is currently enrolling a pivotal cohort across 14 sites in six countries, backed by FDA alignment on an accelerated approval pathway.
• BEAM-304: The program targeting phenylketonuria holds an open Investigational New Drug application, with patient screening scheduled to begin by late 2026.

The Mechanics of Base Editing

Traditional gene editing approaches often rely on double-stranded DNA breaks, which can lead to unintended chromosomal insertions, deletions, or translocations. In contrast, base editing allows molecular machinery to chemically convert single DNA nucleotides, such as swapping a cytosine for a thymine, without cutting the DNA helix.

This precision aims to correct point mutations responsible for monogenic disorders more cleanly than older gene-editing modalities. Executives at the summit emphasized that establishing regulatory frameworks for this class of technology involves demonstrating safety and consistency across multiple editing constructs.

"We should be able, as regulators, to sort of see one set of studies with one editor, let’s say, and once it looks good, we should give you credit for that," Evans said during the discussion.

Capital Allocation and Clinical Horizon

Operating expenses for clinical-stage biotechnology firms remain a primary focus for public markets, particularly as development programs advance into larger, multi-site pivotal trials. Beam Therapeutics reported that its current balance sheet and capital resources are sufficient to support operations and clinical development through mid-2029.

"I think we’re opening a door here to a whole new kind of medicine," Evans stated at the summit.